Shares of Allergan PLC. (NYSE:AGN) have been given an average rating of “Buy” by the twenty-three research firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $274.47.

A number of research firms have recently weighed in on AGN. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup Inc. reaffirmed a “focus list” rating and set a $261.27 price target (up previously from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Deutsche Bank AG reissued a “buy” rating and set a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada boosted their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/allergan-plc-agn-given-average-rating-of-buy-by-analysts/1476394.html.

In other news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. National Investment Services Inc. WI acquired a new stake in Allergan PLC. during the first quarter valued at about $1,731,000. Portland Global Advisors LLC raised its position in Allergan PLC. by 3.0% in the first quarter. Portland Global Advisors LLC now owns 7,581 shares of the company’s stock worth $1,811,000 after buying an additional 223 shares in the last quarter. Howe & Rusling Inc. raised its position in Allergan PLC. by 41.7% in the first quarter. Howe & Rusling Inc. now owns 17,507 shares of the company’s stock worth $4,183,000 after buying an additional 5,149 shares in the last quarter. Addison Capital Co raised its position in Allergan PLC. by 1.9% in the first quarter. Addison Capital Co now owns 10,242 shares of the company’s stock worth $2,447,000 after buying an additional 192 shares in the last quarter. Finally, Oliver Luxxe Assets LLC purchased a new position in Allergan PLC. during the first quarter worth $2,939,000. 84.77% of the stock is owned by institutional investors and hedge funds.

Shares of Allergan PLC. (NYSE AGN) opened at 232.88 on Friday. The firm’s 50-day moving average price is $245.93 and its 200 day moving average price is $238.13. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $78.06 billion, a P/E ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. Allergan PLC.’s quarterly revenue was up 8.8% compared to the same quarter last year. Analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.